Primary tumor resection in the setting of unresectable metastatic disease in small bowel NETs: consensus and controversy
Endocrine-Related Cancer · 01.06.2026 · 33 (6)
DOI: 10.1530/erc-25-0477 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, online erschienen am 08.06.2026. Verfasst von Emilie Ak Warren und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Intestinal Neoplasms, Intestine, Small. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Small bowel neuroendocrine tumors represent a rare malignancy, and most patients present with metastatic disease at diagnosis. While current guidelines from the North American Neuroendocrine Tumor Society and the European Neuroendocrine Tumor Society agree that resection is indicated for symptomatic tumors causing obstruction, ischemia, or bleeding, the role of primary tumor resection in otherwise asymptomatic patients with unresectable metastatic disease remains controversial. This article reviews the existing evidence and highlights the role of primary tumor resection in the setting of metastatic disease. Retrospective studies support mixed findings: some boast a survival advantage for patients undergoing resection of the primary tumor, while others caution that other prognostic factors, including those related to tumor biology, are the true drivers of this benefit. However, it is known that many patients are not truly asymptomatic if a thorough history and physical is performed, and symptom burden can become significant over time. Upfront resection of the primary small bowel tumor prevents development of local complications, such as bowel obstruction or mesenteric vascular compromise, which may require emergency surgery. It has been shown that patients who underwent surgery in the emergent setting (as opposed to elective) had worse survival outcomes and tended to have more incomplete tumor resection and a significantly smaller lymph node yield. Nonetheless, the absence of prospective or randomized controlled studies leaves the value of primary tumor resection unproven, underscoring the critical need for well-designed trials incorporating quality-of-life metrics and obstruction-free survival as key patient-centered outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
- Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.
- Division of Surgical Oncology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
ORCID-Profile: Udhayvir S Grewal, Seth Concors
Zitieren
APA
Warren, E. A., Roorbach, M. D., Ernyey, H., Grewal, U. S., Gangi, A., Halperin, D. M., & Concors, S. (2026). Primary tumor resection in the setting of unresectable metastatic disease in small bowel NETs: consensus and controversy. Endocrine-Related Cancer, 33(6). https://doi.org/10.1530/erc-25-0477
Vancouver
Warren EA, Roorbach MD, Ernyey H, Grewal US, Gangi A, Halperin DM, et al. Primary tumor resection in the setting of unresectable metastatic disease in small bowel NETs: consensus and controversy. Endocrine-Related Cancer. 2026;33(6). doi:10.1530/erc-25-0477
BibTeX
@article{Warren2026,
author = {Warren, Emilie Ak and Roorbach, Madeline D and Ernyey, Helen and Grewal, Udhayvir S and Gangi, Alexandra and Halperin, Daniel M and Concors, Seth},
title = {Primary tumor resection in the setting of unresectable metastatic disease in small bowel NETs: consensus and controversy},
journal = {Endocrine-Related Cancer},
year = {2026},
volume = {33},
number = {6},
doi = {10.1530/erc-25-0477}
}
EUVIMED